Please sign in to follow a disease.
Tuberous sclerosis 1
MONDO:0008612An autosomal dominant syndrome caused by pathogenic variants in the TSC1 gene, characterized by the growth of hamartomas in multiple organs, including the brain, skin, kidneys, heart, and lungs. Other clinical features include seizures, intellectual disability, and skin lesions.
Also known as: TSC1 tuberous sclerosis, TSC1-related tuberous sclerosis, tuberous sclerosis 1, tuberous sclerosis caused by mutation in TSC1, tuberous sclerosis type 1, tuberous sclerosis-1, TSC1, tuberose sclerosis
65 clinical trials for this condition and its sub-types, 33 tagged with Tuberous sclerosis 1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New pill aims to tame seizures in rare brain disorders
Disease control Recruiting nowThis early-stage trial tests an oral drug called SVG103 (Paxalisib) in 15 adults with rare brain conditions (FCD-II, TSC, or HME) that cause seizures. The main goal is to check safety and side effects, while also seeing if it reduces seizure frequency. Participants take the drug …
Phase 1/2 • Sponsor: Sovargen • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a phone app slow kidney disease? new trial aims to find out
Disease control Recruiting nowThis study tests whether a smartphone app can help people with chronic kidney disease (CKD) follow the latest KDIGO treatment guidelines. Researchers will enroll 80 adults aged 16-30 with CKD who own a smartphone. The app provides reminders, education, and care recommendations to…
Sponsor: St. James's Hospital, Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Cannabis oil trial aims to tame seizures in rare genetic disorder
Disease control Recruiting nowThis Phase 3 trial tests a full-spectrum cannabis extract (YCJ-01) in 84 people aged 2 to 65 with tuberous sclerosis complex (TSC) whose seizures have not been controlled by standard treatments. Participants will receive either the cannabis extract or a placebo for two months. Th…
Phase 3 • Sponsor: Oils4Cure • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called Sapu003, given with or without exemestane, in adults with advanced cancers that respond to mTOR pathways—including certain breast, kidney, liver, and neuroendocrine tumors. The main goal is to find the safest dose and check for side …
Phase 1 • Sponsor: SAPU NANO (US) LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Breakthrough hope: drug may stop epilepsy before it starts in TSC infants
Prevention Recruiting nowThis study tests whether giving the drug sirolimus early in life can prevent or delay seizures in infants with tuberous sclerosis complex (TSC). About 64 babies under 7 months old will receive either sirolimus or a placebo. Researchers will track when seizures first appear and mo…
Phase 2 • Sponsor: Darcy Krueger • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
New online therapy aims to tame emotional storms in kids with rare disease
Symptom relief Recruiting nowThis study tests a remote program called Regulating Together (RT) for children aged 8-17 with Tuberous Sclerosis Complex (TSC) who struggle with emotional outbursts. The program uses cognitive behavioral therapy and mindfulness in small group sessions over 5 weeks. Researchers wa…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Scientists dig into why skin tumors grow in rare disease
Knowledge-focused Recruiting nowThis study looks at why people with tuberous sclerosis, a rare genetic condition, develop non-cancerous skin tumors. Researchers will examine up to 400 adults, perform skin exams, and take small tissue samples (biopsies) from tumors. The goal is to identify the cells and genetic …
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Study links gum health to rare kidney diseases
Knowledge-focused Recruiting nowThis study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…
Sponsor: Stefan Lujinschi • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive TSC data and tissue bank opens to researchers
Knowledge-focused Recruiting nowThis study is building a large collection of blood, DNA, and tissue samples along with health records from up to 5,000 people with tuberous sclerosis complex (TSC) or a related condition called lymphangioleiomyomatosis. Participants can give blood or cheek swab samples and allow …
Sponsor: National Tuberous Sclerosis Association • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New italian model aims to ease epilepsy care transition for teens
Knowledge-focused Recruiting nowThis study tests a structured program to help adolescents with epilepsy transition from pediatric to adult healthcare. Researchers will compare how many patients attend their first adult clinic appointment and whether they return to pediatric care. The goal is to improve self-man…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New registry tracks pregnancy risks in rare genetic disorders
Knowledge-focused Recruiting nowThis study collects information from pregnant women with Tuberous Sclerosis Complex (TSC) or Lymphangioleiomyomatosis (LAM) and their babies. Researchers will monitor medication use, side effects, pregnancy complications, and mental health after birth. The goal is to better under…
Sponsor: David M. Ritter • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Could blood particles reveal secrets of rare lung disease LAM?
Knowledge-focused Recruiting nowThis study looks at tiny particles called extracellular vesicles in the blood of women with a rare lung disease called LAM. Researchers want to see if these particles can act as biomarkers to show how the lungs are affected. The study will compare women with different forms of LA…
Sponsor: University of Milan • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC